Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.7B
Close$
$65.68
76.9% downside
Current Fair Value
76.9% downsideOvervalued by 76.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.70 Billion |
|---|---|
| Enterprise Value | $5.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $6.44 |
| Beta | 0.98 |
| Outstanding Shares | 20,063,000 |
Return
| Return on Equity | 19.07% |
|---|---|
| Return on Assets | 8.44% |
| Return on Invested Capital | 10.27% |
Valuation & Multiples
| P/E Ratio | 28.42 |
|---|---|
| PEG | 3.15 |
| Price to Sales | 20.32 |
| Price to Book Ratio | 5.93 |
| Enterprise Value to Revenue | 18.83 |
| Enterprise Value to EBIT | 24.89 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$2.00
Average shareholder expectationRevenue Estimate
$63.99 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.30
Average shareholder expectationRevenue Estimate
$78.09 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8543▲ 2.81% |
|---|---|
| Total Calls | 49,400▲ 17.62% |
| Total Puts | 42,200▲ 21.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 113.73%▲ 9.04% |
|---|---|
| Total Invested | $7.21B▲ 73.51% |
| Investors Holding | 429▲ 61.00% |
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins